Description
Irinotecan is a cytostatic inhibitor of topoisomerase I, semi-synthetic derivative of kamptotecin. It is an antineoplastic agent that acts as a specific inhibitor of DNA topoisomerase I, including lesions of one strand of DNA that blocks replication fork DNA. Besides anticancer activity of Irinotecan, his most important pharmacological effect is blocking acetylcholinesterase.
Indications
Irinotecan is indicated for treatment of patients with advanced colorectal cancer:
– in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease.
– as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.
Subject to medical prescription
Pharmaceutical form: 20 mg/ml concentrate for solution for infusion
